Search clinical trials for: Fluzone I®ntradermal vaccine, 2014-2015 formulation

Total 48 results

Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations (GRC90)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India

Influenza

India
National Institute of Allergy and Infectious Diseases...
Atopic Dermatitis Research Network

Completed

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

Dermatitis, Atopic

United States
Children's Hospital Medical Center, Cincinnati

Completed

Flu Vaccine Study in Neuromuscular Patients 2011

Duchenne Muscular Dystrophy | Spinal Muscular Atrophy | Congenital Muscular Dystrophy
Seqirus

Completed

A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population

Influenza

United Kingdom
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively (GRC00097)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years

Influenza

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine

Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects

Seasonal Influenza

Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects

Seasonal Influenza

Italy
University Health Network, Toronto

Completed

High Dose vs. Standard Influenza Vaccine in Adult SOT

Influenza | Immunosuppression

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Study of Quadrivalent Influenza Vaccine Among Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Safety and Immunogenicity of Fluzone® in Healthy Children

Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

The Influence of Chronic CMV Infection on Influenza Vaccine Responses (SLVP025)

Influenza | Cytomegalovirus Infections

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

Influenza

United States
Seqirus

Completed

A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers

Influenza

United Kingdom
Liquidia Technologies, Inc.
Children's Hospital Medical Center, Cincinnati; Accelovance

Completed

A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001 (LIfT)

Influenza

United States
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

Influenza | Myxovirus Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Quadrivalent Influenza Vaccine Among Children

Influenza

United States
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years

Influenza

United States
PharmaJet, Inc.

Completed

Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe

Influenza Prophylaxis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

Influenza

United States, Puerto Rico
PharmaJet, Inc.

Completed

Jet Injection for Influenza (JIFI)

Influenza, Human

United States
Sanofi Pasteur, a Sanofi Company

Completed

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

B-cell Immunity to Influenza (SLVP017)- Year 1, 2009

Influenza

United States
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old

Influenza

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Influenza Virus Vaccines in Children and Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)

Influenza

France
University of Melbourne

Completed

Influenza Vaccine in HIV Study

Influenza, Human
Sanofi

Completed

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

Influenza | Myxovirus Infection | Orthomyxoviruses

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation

Influenza

Switzerland
National Institute of Allergy and Infectious Diseases...
University of Rochester

Completed

Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines

Influenza, Human

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland

3

Subscribe